Bussiness Ideas
The company is developing an AI-driven urology and uro-gynaecology clinical decision support platform aimed at improving data-driven decision-making in urology care. Current urology practice remains largely reactive, with clinicians relying on fragmented patient data and manual interpretation, leading to delayed interventions, inconsistent outcomes, and increased clinical and operational burden.
The platform initially focuses on predictive analytics for prostate and ovarian cancer, two high-impact areas where false positives, delayed risk identification, and inefficient screening workflows significantly affect patient outcomes and healthcare costs. By analyzing longitudinal patient data such as clinical history, laboratory parameters, imaging summaries, and treatment records, the system generates predictive insights related to disease progression risk, expected treatment timelines, and potential treatment impact. The objective is to support clinicians in risk stratification and care planning while reducing unnecessary procedures and associated anxiety.
Following validation and clinical proof-of-concept, the platform will be expanded to cover a broader range of urology and uro-gynaecology conditions, including benign, chronic, and procedural urology cases. The system is designed as a modular, hospital-grade software solution that integrates with existing clinical workflows and electronic health records. It functions as a decision support tool and does not replace clinical judgment.
The business follows a B2B model, targeting hospitals, speciality clinics, diagnostic centres, and academic medical institutions through subscription and licensing. Continuous clinical feedback and real-world data are used to improve model performance and gradually expand disease coverage, creating a scalable and sustainable urology-focused AI platform.
Show More
